Sumitomo Mitsui Trust Holdings, Inc. Nektar Therapeutics Transaction History

Sumitomo Mitsui Trust Holdings, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 31, 2020	SELL	$15.87 - $23.12 $10.7 Million - $15.7 Million	-677,331 Closed	0 $0
Q3 2019 Oct 31, 2019	SELL	$16.91 - $36.27 $466,868 - $1 Million	-27,609 Reduced 3.92%	677,331 $12.3 Million
Q2 2019 Jul 29, 2019	BUY	$31.0 - $36.3 $699,453 - $819,036	22,563 Added 3.31%	704,940 $25.1 Million
Q1 2019 May 08, 2019	BUY	$31.58 - $46.35 $2.86 Million - $4.19 Million	90,448 Added 15.28%	682,377 $22.9 Million
Q4 2018 Feb 06, 2019	BUY	$30.43 - $56.65 $1.26 Million - $2.35 Million	41,513 Added 7.54%	591,929 $19.9 Million

Q3 2018 Nov 07, 2018	BUY	$46.46 - $68.49 $2.56 Million - $3.77 Million	55,000 Added 11.1%	550,416 $33.6 Million
Q2 2018 Aug 01, 2018	BUY	$46.25 - $104.45 $22.9 Million - $51.7 Million	495,416 New	495,416 $24.2 Million

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Trust Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Sumitomo Mitsui Trust Holdings, Inc. with notifications on news.